Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2014-03-17 Share Issue/Capital Cha…
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
NOMBRE D’ACTIONS ET DE DROITS DE VOTE D’INNATE PHARMA AU 7 MARS 2014
Share Issue/Capital Change Classification · 98% confidence The document is a formal announcement published in French, dated March 17, 2014, titled "NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 7 MARS 2014" (New number of shares and voting rights as of March 7, 2014). It explicitly cites French commercial code and AMF (Autorité des marchés financiers) regulations regarding the publication of the total number of shares and voting rights. This content directly relates to changes in the company's capital structure and shareholder voting power, which aligns best with the 'Share Issue/Capital Change' (SHA) definition, as it reports the current total share count used for voting calculations. Although it involves voting rights, it is a factual update on the share base, not the results of a vote (DVA) or a general capital raising announcement (CAP). Given the focus on the total number of shares and voting rights, SHA is the most precise fit.
2014-03-17 French
Communiqué DSMB
Regulatory Filings Classification · 95% confidence The document is a press release dated March 12, 2014, from Innate Pharma announcing that the Data and Safety Monitoring Board (DSMB) recommended the continuation of the Phase II EFFIKIR trial for Lirilumab. This is an announcement regarding clinical trial progress and safety monitoring, which is a form of corporate update related to R&D and operations. It is not a full financial report (10-K, IR), a formal earnings release (ER), a management discussion (MDA), or a formal regulatory filing like a proxy statement. Since it is a specific operational update that doesn't fit the other specialized categories (like DIV, CAP, DIRS, etc.), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for official company announcements not covered elsewhere, especially those related to clinical milestones or operational news released via press release format.
2014-03-12 French
IPH AG LE 27 MARS 2014 à MARSEILLE
AGM Information Classification · 98% confidence The document is titled "INNATE PHARMA ANNONCE LA TENUE DE SON ASSEMBLÉE GÉNÉRALE ANNUELLE LE 27 MARS 2014 À MARSEILLE" (Innate Pharma announces the holding of its Annual General Meeting on March 27, 2014, in Marseille). It details the date, location, agenda, and procedures for shareholder participation and voting for the Annual General Meeting (AGM). This content directly relates to the materials and announcements surrounding the AGM. Therefore, the most appropriate classification is AGM Information (AGM-R). Although it announces the meeting, the content provides substantial detail about the meeting itself, making it more specific than a general Report Publication Announcement (RPA).
2014-02-19 French
INNATE PHARMA nombre d'actions et de droits de vote au 10 février 2014
Share Issue/Capital Change Classification · 98% confidence The document is a formal announcement titled "NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 10 FÉVRIER 2014" (New Number of Shares and Voting Rights of Innate Pharma as of February 10, 2014). It explicitly cites French regulatory articles (Code de Commerce and AMF regulations) regarding the publication of the total number of shares and voting rights. This content directly relates to changes in the company's capital structure and ownership notification thresholds, which aligns best with the 'Share Issue/Capital Change' (SHA) category, as it details the current share count used for calculating voting rights and potential threshold crossings. Although it involves voting rights, the core subject is the total share count update, making SHA more precise than DVA (which focuses on voting *results*). It is not a general regulatory filing (RNS) because it fits a specific category.
2014-02-12 French
Resultats annuels
Earnings Release Classification · 99% confidence The document is titled 'RÉSULTATS 2013' and provides a detailed summary of financial figures for the fiscal year ended December 31, 2013, including a consolidated income statement table comparing 2013 and 2012 results. It also discusses pipeline progress and financing activities. This content strongly indicates a comprehensive annual financial disclosure. Although it mentions that the full annual financial report will be available later ('Le rapport financier annuel d'Innate Pharma, inclus dans le document de référence, sera mis à disposition au second trimestre 2014'), the current document serves as the primary release of the annual results, which aligns best with the definition of an Annual Report (10-K) or, given the context of a press release format summarizing the year-end figures, it could be an Earnings Release (ER) or an Interim/Quarterly Report (IR) if it were for a shorter period. Since it explicitly covers the full year ('Résultats financiers pour 2013') and contains detailed financial tables, it is the core annual financial disclosure. In the context of US SEC filings, this is analogous to a 10-K filing's content, but since this is a French company press release format, '10-K' is used for the comprehensive annual report. If it were purely a short highlights release, ER would be appropriate, but the inclusion of the full comparative income statement table suggests a deeper report than a typical ER. Given the comprehensive nature covering the full year, 10-K is the most fitting category for a full annual financial performance review. FY 2013
2014-02-11 French
Innate NKG2A
Capital/Financing Update Classification · 95% confidence The document is a press release dated February 5, 2014, announcing a strategic transaction: Innate Pharma acquiring rights to an anti-NKG2A antibody from Novo Nordisk A/S. It details the financial terms (cash, shares, milestones, royalties) and mentions that the acquisition of shares is subject to shareholder approval at an Extraordinary General Meeting (EGM) scheduled for March 27, 2014. The content focuses on a corporate transaction (licensing/acquisition of assets) and associated capital structure changes (issuance of shares to Novo Nordisk, subject to shareholder vote). This strongly suggests a Capital/Financing Update (CAP) or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the specific nature of asset acquisition, financing terms (issuance of shares), and the mention of a required shareholder vote, 'CAP' (Capital/Financing Update) is the most appropriate primary classification, as it details a significant change in corporate financing and structure related to the deal. It is not a standard 10-K, ER, or IR. It is an announcement of a transaction, not a general regulatory filing fallback (RNS).
2014-02-05 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.